We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Notice for satralizumab (Roche Products Pty Limited)
Active ingredients
satralizumab
Sponsor
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
Solution for subcutaneous injection
Indication
Treatment of patients with Neuromyelitis Optica Spectrum Disorder (NMOSD) who are anti aquaporin 4 antibody positive
Therapeutic area
Haematology